"Kanta-Hämeen keskussairaala tarjoaa laadukkaita ja monipuolisia erikoissairaanhoidon palveluita Hämeenlinnan ja Riihimäen yksiköissä. Sinua kuunnellen."

During the past decade, Kanta-Hämeen keskussairaala conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Kanta-Hämeen keskussairaala" are "Anastomotic Complication" (1 trials), "Colectomy" (1 trials), "Colorectal Cancer" (1 trials) and "Parkinson's Disease" (1 trials). Many other conditions were trialed in "Kanta-Hämeen keskussairaala" in a lesser frequency.

Most popular intervention types in "Kanta-Hämeen keskussairaala" are "Drug" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Carbidopa" (1 trials), "Extracorporeal Anastomosis" (1 trials), "Intracorporeal Anastomosis" (1 trials), "Laparoscopic Surgery" (1 trials) and "Robotic Surgery" (1 trials). Other intervention names were less common.

The vast majority of trials in "Kanta-Hämeen keskussairaala" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Kanta-Hämeen keskussairaala". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Kanta-Hämeen keskussairaala, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Kanta-Hämeen keskussairaala, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".